In the present study, we first investigated the molecular consequences of these two rare CF-causing mutations, H609R and [I148T/1023_V1024del]-CFTR, and the efficacy of TRIKAFTATM in restoring function of these variants in HEK-293 cells. The gene discussed is CFTR; the disease is cystic fibrosis.